Drug-protein interactions. Inhibition of the action of levamisole on human serum albumin in vitro by DL-2-oxo-3-(2-mercaptoethyl)-5-phenyl-imidazolidine.
Comparative studies by polyacrylamide gel electrophoresis and immunoelectrophoresis showed that DL-2-oxo-3-(2-mercaptoethyl)-5-phenyl-imidazolidine (OMPI), a major metabolite of levamisole in vivo, exerted an inhibitory effect on the polymerization of albumin induced by levamisole action on human serum in vitro. Similar effects were obtained with sulfhydryl reagents. D-Penicillamine did not indicate such an action. The findings suggest that the SH groups of albumin may be involved in its interaction with levamisole.
D001704:Biopolymers; D001797:Blood Protein Electrophoresis; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D048289:Imidazolidines; D007122:Immunoelectrophoresis; D066298:In Vitro Techniques; D007978:Levamisole / Q000037:antagonists & inhibitors*; D010396:Penicillamine / Q000494:pharmacology; D012709:Serum Albumin / Q000378:metabolism*
D001704:Biopolymers; D007093:Imidazoles; D048289:Imidazolidines; D012709:Serum Albumin; D007978:Levamisole; C019204:OMPI; D010396:Penicillamine